Abstract
Current prognostic models for myelodysplastic syndromes (MDS) do not allow the identification of patients with lower risk disease and poor prognosis that may benefit from early therapeutic intervention. We evaluated the characteristics of 856 patients with low or intermediate-1 disease by the International Prognostic Scoring System. Mean follow-up was 19.6 months (range 1–262). Of these patients, 87 (10%) transformed to acute myelogenous leukemia, and 429 (50%) had died. By multivariate analysis, characteristics associated with worse survival (P<0.01) were low platelets, anemia, older age, higher percent of marrow blasts and poor-risk cytogenetics. Although not included in the model, higher ferritin (P=0.007) and β2-microglobulin (P<0.001) levels were associated with worse prognosis. This allowed the development of a scoring system in which patients could be grouped in three categories: category 1 (n=182, 21%) with a median survival of 80.3 months (95% CI 68-NA); category 2 (n=408, 48%) with a median survival of 26.6 months (95% CI 22–32) and category 3 (n=265, 31%) with a median survival of 14.2 months (95% CI 13–18). In summary, this analysis indicates that it is possible to identify patients with lower risk MDS and poor prognosis who may benefit from early intervention.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199.
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999; 10: 1419–1432.
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sang G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.
Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429–2440.
List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465.
Kantarjian H, Issa JP, Rosenfeld CS, Bennett J, Albitar M, Dipersion J et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794–1803.
Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170.
Cox D . Regression models and life tables. J R Stat Soc B 1972; 34: 187–220.
Grambsch P, Therneau T . Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515–526.
Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52–57.
Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E . Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005; 106: 803–811.
Jadersten M, Malcovati L, Dybedal I, Giovanni M, Invernizzi R, Montgomery S et al. Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need. Blood 2006; 108: 158a [abstract 521].
Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104: 579–585.
Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594–7603.
Gatto S, Ball G, Onida F, Kantarjian HM, Estey EH, Beran M . Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS). Blood 2003; 102: 1622–1625.
Acknowledgements
GG-M is supported in part by a Physician-Scientist Award funded by the Commonwealth Cancer Foundation for Research and a Leukemia and Lymphoma Translational Research Grant no. 6173-07. This work was also supported in part by NCI grant 5P01 CA108631. GG-M designed the study, analyzed data and wrote the manuscript; JS analyzed the data and performed statistical analysis; SF, JC, FR-K, GB, SP, EE analyzed data and helped in the writing of the manuscript; HK analyzed data and wrote the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Garcia-Manero, G., Shan, J., Faderl, S. et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22, 538–543 (2008). https://doi.org/10.1038/sj.leu.2405070
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2405070
Keywords
This article is cited by
-
Fetal hemoglobin level predicts lower-risk myelodysplastic syndrome
International Journal of Hematology (2023)
-
Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes
Modern Pathology (2022)
-
New Approaches to Myelodysplastic Syndrome Treatment
Current Treatment Options in Oncology (2022)
-
Current challenges and unmet medical needs in myelodysplastic syndromes
Leukemia (2021)
-
Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes
Journal of Patient-Reported Outcomes (2020)